 Study Endpoints: The primary endpoint is safety and tolerability of the regimen. The secondary immunogenicity endpoint is H5-specific antibody as measured by hemagglutination inhibition HAI assay at Study Week 12. H5-specific T cell responses measured by intracellular cytokine staining ICS assay, enzyme-linked immunospot ELISPOT assays and other immunogenicity assays at timepoints throughout the study may also be completed as exploratory evaluations. 